Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, treatment with IL-2C to expand Tregs effectively halted hair loss progression in a murine model of alopecia areata.

In a mouse model, this study found that LAM/TSC cells invaded the uterus and increased angiogenesis, while anti-EGFR antibody and rapamycin effectively reduced cell presence and blood vessel proliferation.

This paper reviews three cases of traumatic anserine folliculosis in children, showing the condition's association with postural habits and potential improvement through posture correction and topical treatments.

In this study, researchers found that TCDD exposure accelerated differentiation and altered gene expression in human epidermal cells, indicating the epidermal barrier as a target of TCDD-activated AHR.

This article reviews antibody drug conjugates for cancer treatment, describing their mechanism, recent approvals, and ongoing research efforts, but reports no new clinical results.

This study found that tadalafil use was associated with a decreased risk of major adverse cardiac events and venous thromboembolism in men with lower urinary tract symptoms.

In this article, two case studies of hair tourniquets around digits are discussed, highlighting the condition's potential causes and management strategies, and emphasizing the role of midwives and health visitors in educating expectant mothers to minimize the risk to children.

This study observed that expanding regulatory T cells in the skin of mice with alopecia areata did not reverse the condition, indicating that additional immunotherapy may be necessary.

This case report describes a girl diagnosed with ADULT syndrome, highlighting its rarity, varied presentation, and the importance of early diagnosis to prevent unnecessary stress and medical expenses.

This study found that telocytes in human scalp tissue were located around hair follicles and glands and may be involved in skin regeneration and homeostasis.

This study suggests that targeting skin-infiltrated memory phenotype T cells could offer a new therapeutic approach to manage lymphopenia-related diseases like graft-versus-host disease and immune reconstitution inflammatory syndrome.

This study suggests that topical T3 can induce hair follicles to enter the growth phase and may reverse graying in mice, with in vitro results supporting enhanced hair shaft growth.

This study observed that tannic acid significantly reduced hair shedding by 56.2% over seven days in human participants when used as a coating for controlled release of active compounds to hair follicles.

In this study, oxidation hair dye formulations tested on mice showed no evidence of causing systemic toxicity or cancer over an 18-month period.

This case report found that a 48-year-old woman with idiopathic twenty-nail dystrophy experienced significant improvement in nail appearance after six months of treatment with oral Upadacitinib.

In this study, tofacitinib treatment led to significant hair regrowth in 60% of patients with moderate-to-severe alopecia areata, suggesting potential for JAK inhibitors in treating this condition.

In this report, two young patients with corticosteroid-refractory alopecia totalis experienced safety and efficacy from oral tacrolimus.

This study found that upadacitinib significantly improved hair regrowth compared to placebo in adults and adolescents with severe alopecia areata, and demonstrated a positive benefit-risk profile.

This study is collecting real-world data to evaluate abrocitinib and conventional systemic treatments in moderate-to-severe atopic dermatitis across five European registers over a three-year period.

Tanshinone IIA helps protect skin tissue from low oxygen damage by boosting certain cell markers.

This review discusses the causes and diagnosis of traction alopecia, emphasizing education for high-risk populations as there is currently no cure, and presents no new clinical findings.

This study aimed to evaluate the outcomes of switching between two JAK inhibitors, tofacitinib and baricitinib, in treating alopecia areata, due to the lack of data on their comparative efficacy.

Tofacitinib, an arthritis drug, helped hair growth in alopecia universalis but long-term safety needs more research.

In this retrospective study, oral tofacitinib treatment for at least 6 months improved scalp hair loss in 69.1% of alopecia areata patients, with patchy AA cases responding better compared to other subtypes, and no significant adverse effects were reported.

This report describes a rare case of tumoral calcinosis presenting as a slow-growing mass on the scalp in an Afro-Caribbean man, with histopathology revealing calcium deposits and associated tissue changes.

This study found that traction alopecia risk was higher in adults than children and increased further when traction was combined with chemically relaxed hair.

This study describes a case where a patient with alopecia totalis treated with the JAK inhibitor tofacitinib showed hair regrowth but experienced worsened facial acne.

This article is a letter to the editor discussing potential therapeutic synergy between a wig-fixing device and tofacitinib for treating alopecia areata but reports no new clinical results.

The researchers reported a case where treatment with tofacitinib improved both hair loss and skin lesions in a patient with Graham-Little-Piccardi-Lassueur Syndrome and hidradenitis suppurativa over six months, with no recurrence or adverse events during two-year follow-up.